SCHEMBL15096337

SCHEMBL15096337

Cc1cccc(Oc2ccc(C=O)cc2C)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.51
MAOA P21397 2/20 0.48
MAOB P27338 2/20 0.48
ALDH1A1 P00352 5/20 0.47
GAA P10253 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
LMNA P02545 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
AR P10275 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
TSHR P16473 1/20 0.42
ACHE P22303 1/20 0.42
HTT P42858 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CASP1 P29466 1/20 0.40
AOX1 Q06278 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8498710 0.85 TTR (0.69) TTRMAOAMAOBALDH1A1GAA
Metacresol SCHEMBL9230543 0.85 TTR (0.53) TTRMAOAMAOBALDH1A1GAA
SCHEMBL14667749 0.85 TTR (0.49) TTRMAOAMAOBALDH1A1GAA
SCHEMBL29862575 0.85 TTR (0.73) TTRMAOAMAOBALDH1A1GAA
SCHEMBL9889483 0.85 TTR (0.73) TTRMAOAMAOBALDH1A1GAA
SCHEMBL1745573 0.82 MAOA (0.62) MAOAMAOBALDH1A1GAAL3MBTL1
SCHEMBL30644969 0.82 MAOA (0.62) MAOAMAOBALDH1A1GAAL3MBTL1
SCHEMBL9889485 0.81 AR (0.47) TTRMAOAMAOBALDH1A1GAA
SCHEMBL9889480 0.81 AR (0.56) TTRMAOAMAOBALDH1A1GAA
SCHEMBL875544 0.81 ALDH1A1 (0.57) TTRALDH1A1L3MBTL1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 TTR 913/4885MAOA 349/4885MAOB 510/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 TTR 913/4885MAOA 349/4885MAOB 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.